Santarus 8-K 2013
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 20, 2013
(Exact Name of Registrant as Specified in Its Charter)
3611 Valley Centre Drive, Suite 400, San Diego, California 92130
(Address of Principal Executive Offices) (Zip Code)
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On June 20, 2013, Santarus, Inc., the University of Missouri and Dr. Reddys Laboratories, Ltd. and Dr. Reddys Laboratories, Inc. (collectively, Dr. Reddys) entered into a settlement and license agreement (the Settlement Agreement) to resolve pending patent litigation involving the prescription product Zegerid® (omeprazole/sodium bicarbonate) Capsules.
The Settlement Agreement grants Dr. Reddys the right to begin selling a generic version of prescription Zegerid Capsules on July 16, 2016 (following expiry of U.S. Patent No. 7,399,772), or earlier under certain circumstances. The Settlement Agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, as well as entry by the U.S. District Court for the District of New Jersey of an order dismissing the litigation.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.